Jushi Holdings Inc - CEO, Jim Cacioppo
CEO, Jim Cacioppo
Source: YouTube (OTC Markets Group)
  • Jushi Holdings Inc. (JUSH) closes a US$3.68 million private placement with Kenneth Rosen and group
  • The company issued one million subordinate voting shares at a price of US$3.68 per share
  • Rosen has participated in several rounds of the company’s financings and is one of its top investors
  • As of December 31, 2021, Jushi Holding’s pro forma cash balance was approximately US$107.7 million
  • Jushi Holdings Inc. (JUSH) is up 7.66 per cent trading at $5.20 per share as of 2:52 p.m. EST

Jushi Holdings (JUSH) has closed a US$3.68 million private placement with Kenneth Rosen and group.

The company issued one million subordinate voting shares at a price of US$3.68 per share.

Jushi Holdings is a vertically integrated cannabis company led by an industry-leading management team.

Rosen, a long-term strategic investor in Jushi Holdings, has participated in several rounds of the company’s financings and is one of its top investors.

Jim Cacioppo, CEO, Chairman, and founder of Jushi, commented,

“As long-time, early investors in Jushi, and highly regarded lenders in the cannabis industry, we are incredibly pleased to have once again secured the support of Ken Rosen and group. With this additional funding, we remain focused on strengthening our platform and accelerating our growth plans to attract increased institutional backing and engagement.”

As of December 31, 2021, Jushi Holding’s pro forma cash balance was approximately US$107.7 million.

The company’s acquisition facility, following its Nevada transaction closings, will have approximately US$63 million of available capacity including the US$25 million accordion feature.

Jushi Holdings Inc.(JUSH) is up 7.66 per cent trading at $5.20 per share as of 2:52 p.m. EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.